estradiol valerate

P=N/A, N=20, Active, not recruiting, Thai Red Cross AIDS Research Centre | Trial primary completion date: Oct 2023 --> Jan 2024

P4, N=362, Active, not recruiting, CRG UZ Brussel | Recruiting --> Active, not recruiting | N=522 --> 362

P=N/A, N=290, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital

P3, N=120, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

SMLE showed strong in vitro antioxidant activity which corroborated its in vivo antioxidant activity. The study showed that S. malaccense could be useful in the management of BPH.

This study demonstrates that GFP alleviates ovariectomy-induced osteoporosis via reduced secretion of inflammatory cytokines, improvement in the oxidative stress status in the body, and inhibition of the PINK1/Parkin signaling pathway.

P=N/A, N=32, Completed, International Research Training Group 2804

P=N/A, N=74, Recruiting, International Research Training Group 2804 | Not yet recruiting --> Recruiting

P4, N=554, Recruiting, Universitaire Ziekenhuizen KU Leuven | Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Apr 2024

P=N/A, N=74, Not yet recruiting, International Research Training Group 2804

P=N/A, N=4, Terminated, St. Louis University | Trial completion date: Dec 2024 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jan 2023; lack of recruitment

Estradiol Valerate (EV) was used to induce cervical hyperkeratosis. Histopathological picture of diffuse and marked hyperkeratosis was detected in EV and GEN groups. In conclusion, GEN-induced cervical hyperkeratosis via induction of oxidative stress, inflammation and apoptosis.

P4, N=150, Recruiting, Mansoura University | Unknown status --> Recruiting | Trial completion date: Mar 2021 --> Dec 2024 | Trial primary completion date: Jan 2021 --> Dec 2024

ZGP and YGP represent novel anti-PMS agents whose effects involve restoring altered hormonal levels, protecting the uterus, and regulating apoptosis.

EPA in the used doses provided biochemical and histopathological improvement in EV-induced EH via modulation of NF-κB/HIF-1α/VEGF signaling pathway.

E2/NETA and CEE treatments gave a 4-7-old increase in proliferation during treatment (p = 0.04) and (p = 0.007), respectively, which was absent in the E2V/LNG group, showing a significant correlation with insulin-like growth factor binding protein-3 (IGFBP-3) serum levels. Conclusion E2V in combination with very low serum concentrations of LNG in the IUS gives no increase in proliferation in the normal breast.

Case Presentation: We are presenting a 53-year-old Male to Female transgender patient who has been receiving estradiol valerate injections every 14 days for 13 years and had no gender surgical reassignment procedures or breast implants...Breast cancer in MTF transgender patients is associated with receiving CHT and represents diagnostic and treatment challenge. More research is need to comment on routine breast cancer screening in this population. However, physicians should remember performing a regular breast exam in MTF individuals looking for a possible mass.

Conclusion This study demonstrated that 3PFBPA ameliorates OV-induced uterine hyperplasia in the female Wistar rat model. The findings warrant further investigation of the antifibrotic effects of 3PFBPA in humans.

The endometrium showed a regression of the proliferative epithelium with the restoration of PTEN expression and the absence of the atypical features. In conclusion, febuxostat protected the endometrium against estrogen-induced EH and may be beneficial in the management along with the hormonal therapy.

Case Presentation: We are presenting a 53-year-old Male to Female transgender patient who has been receiving estradiol valerate injections every 14 days for 13 years and had no gender surgical reassignment procedures or breast implants... Breast cancer in MTF transgender patients is associated with receiving CHT and represents diagnostic and treatment challenge. More research is need to comment on routine breast cancer screening in this population. However, physicians should remember performing a regular breast exam in MTF individuals looking for a possible mass.

Also, uterine iNOS and Ki67 expressions were markedly suppressed. In conclusion, upregulation of HO-1 expression via hemin has ameliorative effect against EH through its anti-oxidant, anti-inflammatory and anti-proliferative actions.